Evidence map›Paper›PMID 40013390›Full record

ArticleHaematologica2025

Prognostic relevance of variant allele frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry.

Rafael Colmenares, Noemi Alvarez, Eva Barragan, Blanca Boluda, Maria J Larrayoz, Maria Carmen Chillon, Elena Soria-Saldise, Cristina Bilbao, Joaquin Sanchez-Garcia, Teresa Bernal and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Pandora's Box of AML: HowBiomedicines · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Rafael ColmenaresHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid.
Noemi AlvarezHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid.
Eva BarraganMolecular Biology Unit, Hospital Universitari i Politecnic-IIS La Fe, Valencia.
Blanca BoludaHematology Department, Hospital Universitari i Politecnic-IIS La Fe, CIBERONC, Valencia.
Maria J LarrayozCIMA LAB Diagnostics-Universidad de Navarra, Pamplona.
Maria Carmen ChillonHospital Universitario de Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca.
Elena Soria-SaldiseHospital Universitario Virgen del Rocio, Instituto de Biomedicina (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Sevilla.
Cristina BilbaoHospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria.
Joaquin Sanchez-GarciaIMIBIC, Hematology, Hospital Universitario Reina Sofia, UCO, Cordoba.
Teresa BernalHospital Universitario Central de Asturias, Instituto Universitario (IUOPA), Instituto de investigacion del Principado de Asturias (ISPA), Oviedo.
David Martinez-CuadronHematology Department, Hospital Universitari i Politecnic-IIS La Fe, CIBERONC, Valencia.
Cristina GilHospital General Universitario de Alicante, Alicante.
Josefina SerranoIMIBIC, Hematology, Hospital Universitario Reina Sofia, UCO, Cordoba.
Carlos Rodriguez-MedinaHospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria.
Juan BerguaHospital Universitario San Pedro de Alcantara, Caceres.
Jose A Perez-SimonHospital Universitario Virgen del Rocio, Instituto de Biomedicina (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Sevilla.
Maria CalbachoHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid.
Juan M Alonso-DominguezHospital Universitario Fundacion Jimenez Diaz, Madrid.
Jorge LabradorResearch Unit, Hematology Department, Hospital Universitario de Burgos, Universidad Isabel I, Burgos.
Mar TormoHematology Department, Hospital Clinico Universitario-INCLIVA, Valencia.
Pilar Herrera-PuenteHospital Universitario Ramon y Cajal, Madrid.
Cristina Martin-ArriscadoInstituto de Investigacion Hospital 12 de Octubre, i+12, Madrid.
Andres Arroyo-BareaHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid.
Inmaculada RapadoHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid.
Claudia SargasMolecular Biology Unit, Hospital Universitari i Politecnic-IIS La Fe, Valencia.
Iria VazquezCIMA LAB Diagnostics-Universidad de Navarra, Pamplona.
Maria J CalasanzCIMA LAB Diagnostics-Universidad de Navarra, Pamplona.
Teresa Gomez-CasaresHospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria.
Ramon Garcia-SanzHospital Universitario de Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca.
Rebeca Rodriguez-VeigaHematology Department, Hospital Universitari i Politecnic-IIS La Fe, CIBERONC, Valencia.
Joaquin Martinez-LopezHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid.
Rosa AyalaHematology Department, Hospital Universitario 12 de Octubre, i+12, CNIO, CIBERONC, Complutense University, Madrid. rayala@ucm.es.
Pau MontesinosHematology Department, Hospital Universitari i Politecnic-IIS La Fe, CIBERONC, Valencia. montesinos_pau@gva.es.
Pethema Group.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40013390
PMCPMC12208151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.